Edition:
United States

Ironwood Pharmaceuticals Inc (IRWD.OQ)

IRWD.OQ on NASDAQ Stock Exchange Global Select Market

12.91USD
18 Jan 2019
Change (% chg)

$0.00 (+0.00%)
Prev Close
$12.91
Open
$13.12
Day's High
$13.30
Day's Low
$12.68
Volume
499,850
Avg. Vol
467,949
52-wk High
$21.19
52-wk Low
$9.16

Latest Key Developments (Source: Significant Developments)

Ironwood Pharmaceuticals Announces Approval Of Linzess® (Linaclotide) In China For The Treatment Of Adults With Ibs-C
Tuesday, 15 Jan 2019 08:00am EST 

Jan 15 (Reuters) - Ironwood Pharmaceuticals Inc ::IRONWOOD PHARMACEUTICALS ANNOUNCES APPROVAL OF LINZESS® (LINACLOTIDE) IN CHINA FOR THE TREATMENT OF ADULTS WITH IBS-C.IRONWOOD PHARMACEUTICALS - ANTICIPATES WILL LAUNCH LINZESS WITH ITS PARTNER IN CHINA, ASTRAZENECA, IN H2 2019.  Full Article

Ironwood Pharmaceuticals Says Mark Mallon To Become Ceo
Friday, 4 Jan 2019 12:05pm EST 

Jan 4 (Reuters) - Ironwood Pharmaceuticals Inc ::IRONWOOD PHARMACEUTICALS ANNOUNCES CHIEF EXECUTIVE OFFICERS TO LEAD IRONWOOD AND CYCLERION, EFFECTIVE UPON UPCOMING SEPARATION.IRONWOOD PHARMACEUTICALS INC - MARK MALLON TO BECOME CEO OF IRONWOOD.IRONWOOD PHARMACEUTICALS INC - PETER HECHT, FOUNDER AND CURRENT CEO OF IRONWOOD, TO BECOME CEO OF CYCLERION.IRONWOOD PHARMACEUTICALS INC - SEPARATION ON TRACK FOR COMPLETION IN FIRST HALF OF 2019.IRONWOOD PHARMACEUTICALS INC - MALLON JOINS IRONWOOD FOLLOWING A CAREER AT ASTRAZENECA.  Full Article

Ironwood Pharmaceuticals Picks AstraZeneca Executive Mallon To Be Next CEO- WSJ
Friday, 4 Jan 2019 11:13am EST 

Jan 4 (Reuters) - :IRONWOOD PHARMACEUTICALS PICKS ASTRAZENECA EXECUTIVE TO BE NEXT CEO - WSJ.MARK MALLON IS SLATED TO JOIN IRONWOOD AS CEO - WSJ, CITING SOURCES.  Full Article

Ironwood Pharmaceuticals Reports Q3 Loss of $1.14 Per Share
Tuesday, 6 Nov 2018 08:09am EST 

Nov 6 (Reuters) - Ironwood Pharmaceuticals Inc ::IRONWOOD PHARMACEUTICALS PROVIDES THIRD QUARTER 2018 INVESTOR UPDATE.Q3 REVENUE $66 MILLION.Q3 REVENUE VIEW $94.7 MILLION -- THOMSON REUTERS I/B/E/S.ON TRACK TO COMPLETE SEPARATION OF IRONWOOD INTO TWO INDEPENDENT, PUBLICLY TRADED COMPANIES IN FIRST HALF 2019.FOLLOWING LESINURAD DEAL TERMINATION NOTIFICATION, IRONWOOD INITIATED A REDUCTION IN ITS WORKFORCE.TOTAL COSTS RELATED TO REDUCTION IN WORKFORCE WERE APPROXIMATELY $7.6 MILLION DURING Q3.SEES FY SG&A EXPENSES TO BE IN RANGE OF $230 MILLION TO $250 MILLION.NOW EXPECTS FY TOTAL RESTRUCTURING COSTS TO BE APPROXIMATELY $16 MILLION.QTRLY LOSS PER SHARE $1.14.Q3 EARNINGS PER SHARE VIEW $-0.17 -- THOMSON REUTERS I/B/E/S.  Full Article

Ironwood Pharmaceuticals Announces FDA Fast Track Designation For Praliciguat For The Treatment Of Heart Failure With Preserved Ejection Fraction (Hfpef)
Thursday, 13 Sep 2018 08:00am EDT 

Sept 13 (Reuters) - Ironwood Pharmaceuticals Inc ::IRONWOOD PHARMACEUTICALS ANNOUNCES FDA FAST TRACK DESIGNATION FOR PRALICIGUAT FOR THE TREATMENT OF HEART FAILURE WITH PRESERVED EJECTION FRACTION (HFPEF).IRONWOOD PHARMACEUTICALS INC - PRALICIGUAT PHASE II TRIAL IN HFPEF CONTINUES TO ENROLL PATIENTS WITH TOPLINE DATA EXPECTED IN SECOND HALF OF 2019.  Full Article

Ironwood Announces Management Changes Related To Separation Of Soluble Guanylate Cyclase Business From Commercial, Gastrointestinal Business
Tuesday, 12 Jun 2018 04:37pm EDT 

June 12 (Reuters) - Ironwood Pharmaceuticals Inc ::IRONWOOD - ANNOUNCED MANAGEMENT CHANGES RELATED TO SEPARATION OF SOLUBLE GUANYLATE CYCLASE BUSINESS FROM COMMERCIAL, GASTROINTESTINAL BUSINESS.IRONWOOD SAYS WILL SEPARATE SOLUBLE GUANYLATE CYCLASE BUSINESS INTO 2 PUBLICLY TRADED COMPANIES 'RESEARCH AND DEVELOPMENT CO' AND 'NEW IRONWOOD' - SEC FILING.IRONWOOD PHARMACEUTICALS - EFFECTIVE UPON SEPARATION WILLIAM HUYETT TO BECOME CFO OF RESEARCH AND DEVELOPMENT CO.IRONWOOD PHARMACEUTICALS - GINA CONSYLMAN TO CONTINUE AS CFO OF NEW IRONWOOD.  Full Article

Nicox Announces Research Collaboration With Ironwood Pharmaceuticals
Wednesday, 6 Jun 2018 01:30am EDT 

June 6 (Reuters) - NICOX SA ::REG-NICOX ANNOUNCES RESEARCH COLLABORATION ON NOVEL OPHTHALMIC THERAPEUTICS WITH IRONWOOD PHARMACEUTICALS.EACH COMPANY WILL BE RESPONSIBLE FOR THEIR OWN COSTS ASSOCIATED WITH ACTIVITIES CARRIED OUT AS PART OF COLLABORATION.DEPENDING ON OUTCOME, COS MAY ENTER INTO DISCUSSIONS ON NICOX'S FURTHER DEVELOPMENT OF ANY IDENTIFIED PRODUCT CANDIDATE..  Full Article

Ironwood Pharmaceuticals Qtrly GAAP Net Income Per Share $0.08
Thursday, 15 Feb 2018 08:01am EST 

Feb 15 (Reuters) - Ironwood Pharmaceuticals Inc ::Q4 REVENUE $94.2 MILLION.‍EXPECT TO GENERATE POSITIVE CASH FLOW IN 4Q 2018​.QTRLY TOTAL REVENUES $94.2 MILLION VERSUS $87.5 MILLION.QTRLY GAAP NET INCOME PER SHARE BASIC AND DILUTED $0.08 ‍​.Q4 REVENUE VIEW $88.9 MILLION -- THOMSON REUTERS I/B/E/S.EXPECTS TO USE LESS THAN $75 MILLION IN CASH FOR OPERATIONS IN 2018 ‍​.  Full Article

Sun Pharmaceutical Industries Announces Settlement Of Patent Litigation For Generic Linzess In U.S.
Tuesday, 16 Jan 2018 08:38am EST 

Jan 16 (Reuters) - Sun Pharmaceutical Industries Ltd ::SAYS CO'S UNITS HAVE REACHED AN AGREEMENT WITH IRONWOOD PHARMACEUTICALS, INC. AND ALLERGAN PLC.ANNOUNCES SETTLEMENT OF PATENT LITIGATION FOR GENERIC LINZES IN US.COMPANIES TO GRANT CO'S UNITS LICENSE TO MARKET GENERIC VERSION OF LINZESS IN U.S FROM FEB 1, 2031 OR EARLIER UNDER CIRCUMSTANCES.ADDITIONAL DETAILS REGARDING THE SETTLEMENT WERE NOT DISCLOSED..  Full Article

Allergan, Ironwood Announce Settlement With Sun Pharma
Tuesday, 16 Jan 2018 08:30am EST 

Jan 16 (Reuters) - Allergan Plc ::IRONWOOD AND ALLERGAN ANNOUNCE SETTLEMENT WITH SUN PHARMA RESOLVING LINZESS® (LINACLOTIDE) PATENT LITIGATION.SAYS PER SETTLEMENT TERMS, IRONWOOD, CO TO GRANT UNITS OF SUN PHARMA LICENSE TO MARKET GENERIC VERSION OF LINZESS IN U.S. BEGINNING FEB 1, 2031​.SAYS ‍ADDITIONAL DETAILS REGARDING SETTLEMENT WERE NOT DISCLOSED​.SAYS IRONWOOD PHARMACEUTICALS, CO ANNOUNCED COMPANIES REACHED AN AGREEMENT WITH WHOLLY-OWNED UNITS OF SUN PHARMACEUTICAL INDUSTRIES.SAYS ‍AS A RESULT OF SETTLEMENT, ALL HATCH-WAXMAN LITIGATION BETWEEN COMPANIES AND SUN PHARMA REGARDING LINZESS PATENTS TO BE DISMISSED​.  Full Article